Metformina Pensa

Metformin, the active ingredient in Metformina Pensa, is a biguanide presented as an oral tablet for oral use. It is employed to lower elevated blood glucose levels in adults with type 2 diabetes mellitus. The medication works by decreasing hepatic glucose production and improving peripheral insulin sensitivity, helping patients achieve better glycemic control.

GNH USA supplies Metformina Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance and timely delivery.

Metformina Pensa (metformin) is used in the management of disorders related to glucose metabolism, primarily type 2 diabetes mellitus.

Type 2 diabetes mellitus: improves glycemic control by reducing hepatic glucose output and enhancing insulin sensitivity.

Metformina Pensa may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramps or pain. - Metallic taste: altered taste sensation.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe hypoglycemia: especially when combined with other glucose‑lowering agents. - Skin reactions: such as rash or Stevens‑Johnson syndrome (very rare).

When prescribing Metformina Pensa, clinicians should consider several safety aspects. - Renal function: assess creatinine clearance before initiating therapy. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: monitor for signs of heart failure. - Alcohol consumption: avoid excessive intake due to increased risk of lactic acidosis. - Pregnancy and lactation: safety not established; evaluate risk‑benefit. - Store at ambient temperature: keep in original container, protect from moisture and light.

Metformina Pensa can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Certain antiretrovirals (e.g., didanosine): heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (thiazides): can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function when combined.